Press Release

For Advion:
Kathryn Henion
Advion BioSciences, Inc.
607.266.0665
henionk@advion.com
http://www.advion.com

Denise J. Herich
Hill & Knowlton, for Correlogic Systems
202.944.3367
denise.herich@hillandknowlton.com

Media Contact:

May 14, 2003

Correlogic Systems To Explore Use of Advion BioSciences’ NanoMate™ System In Groundbreaking Ovarian Cancer Detection Tests: Researchers Hope for Another '100 Percent Detection Success' Story

BETHESDA, MD – May 14, 2003 — Correlogic Systems, Inc., the developer of promising new cancer detection tests that use just a single drop of blood from a patient, has entered into an agreement with Advion BioSciences, a leading provider of mass spectrometry services and products, to explore the use of Advion’s NanoMate™ System as a component of Correlogic’s upcoming ovarian cancer clinical trials.

Correlogic’s test, called Proteome Pattern Blood TestSM, scans a drop of blood for protein patterns generated by a mass spectrometer. In February 2002, Correlogic Systems earned international recognition when its joint research with the National Cancer Institute (NCI) and the Food and Drug Administration (FDA) revealed that the Correlogic test successfully detected all of the ovarian cancer patients in a study of 216 women, including cancers that were still in Stage 1. On April 9, 2003, NCI announced that Correlogic, NCI, and FDA scientists have achieved further improved results. The team was able to detect ovarian cancer with 100 percent accuracy—again identifying all of the cases of ovarian cancer—but without any false positives.

The goal of the Correlogic-Advion research is to determine whether results similar to those published in February 2002 can be replicated on the NanoMate system and thereby employed in the NCI-sponsored clinical trials scheduled to begin soon.

According to Jack Henion, president of Advion, "The NanoMate 100 is an ideal tool for consideration in Correlogic’s clinical trials because it is a simple-to-use, automated nanoelectrospray platform that promises to increase the throughput and quality of the analysis."

Peter Levine, president and chief executive officer of Correlogic Systems, Inc., indicated that the benefits of greater process automation, efficiency and capacity to handle test demand make Advion’s technology a smart choice. "This agreement is about getting the most accessible and accurate ovarian cancer test to every woman who needs it," Levine said. "If the results of our joint research and validation studies confirm what we believe to be the case, the public will benefit enormously."

Advion and Correlogic have already begun the research and validation process, and will detail results to date at the American Society of Mass Spectrometry Conference to be held June 8, 2003.

About Correlogic Systems, Inc.

Correlogic Systems, Inc. is a Bethesda, Maryland-based BioIT company that has developed patent-pending pattern recognition and pattern discovery software and processes with a wide variety of applications for bio-marker discovery, disease detection, and new drug discovery. The technology’s first application has been in the field of proteomics – the study of human proteins – with concentration on the early detection of prostate, ovarian, breast and other cancers. The Correlogic Proteome Pattern Blood TestSM is a cutting edge approach to disease detection, using Correlogic’s proprietary hidden patterns technology including ProteomeQuest™ and ProteomeDx™. Correlogic has entered into licensing agreements with Quest Diagnostics, Inc. (NYSE: DGX) and Laboratory Corporation of America (NYSE: LH) for the commercialization of Correlogic’s ovarian cancer protein pattern blood test. Visit Correlogic Systems at www.correlogic.com.

About Advion BioSciences

Advion BioSciences Inc., of Ithaca, N.Y., is a leading provider of mass spectrometry services to the pharmaceutical industry, and a developer of automated, chip-based technology designed to boost the sensitivity, data quality and sample throughput for electrospray mass spectrometers. Operating one of the world's largest LC/MS contract research facilities, Advion's clients include 13 of the top 15 pharmaceutical companies. Visit Advion BioSciences at www.advion.com.

Cautionary Statement:

Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Actual results could differ materially due to, among other things, operational and other difficulties associated with integrating acquired business, general business conditions, competition among managed care companies, rising health costs, trends in medical loss ratios, health care reform, delay in receipt of regulatory and other approvals for pending transactions and other regulatory issues.